Back to results
US 2023/0405134 A1Published application
Novel protac chimeric compound, and pharmaceutical composition comprising same for preventing, ameliorating, or treating diseases through target protein degradation
AssigneePostech Research and Business Development Foundation
InventorsHyun Suk LIM, Yeong Ju LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel class of a chimeric molecule associated with a chimeric compound design for degrading a desired target protein, SRC-1. More specifically, the present invention relates to a peptide compound for degrading SRC-1 protein, and a pharmaceutical composition for preventing or treating cancer metastasis and occurrence caused by SRC-1 overexpression, and for preventing or treating immune-related diseases.
Claims16
A chimeric compound having a structure of Formula 1 below:
- wherein:
- A represents a ubiquitin ligase binding moiety (ULM) that binds to any one or more E3 ubiquitin ligases selected from the group consisting of ubiquitin-protein ligase E3 component n-recognin 1 (UBR1), ubiquitin-protein ligase E3 component n-recognin 2 (UBR2) and ubiquitin-protein ligase E3 component n-recognin 4 (UBR4), and
- B represents a protein target moiety (PTM) that binds to steroid receptor coactivator-1 (SRC-1), wherein A and B are chemically linked by a linker.
Dependencies are inferred from the claim text.